Abstract
Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.
Keywords: Anacetrapib, cholesteryl, ester, transfer-protein, inhibitor, Dyslipidemia, cardiovascular disease, cholesterol, blood pressure, plasma
Current Clinical Pharmacology
Title: Anacetrapib: A New Weapon Against Dyslipidemia
Volume: 6 Issue: 4
Author(s): Georgios Aperis, Christos Paliouras, Eirini Tsampikaki, Nikolaos Papakonstantinou and Polichronis Alivanis
Affiliation:
Keywords: Anacetrapib, cholesteryl, ester, transfer-protein, inhibitor, Dyslipidemia, cardiovascular disease, cholesterol, blood pressure, plasma
Abstract: Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.
Export Options
About this article
Cite this article as:
Aperis Georgios, Paliouras Christos, Tsampikaki Eirini, Papakonstantinou Nikolaos and Alivanis Polichronis, Anacetrapib: A New Weapon Against Dyslipidemia, Current Clinical Pharmacology 2011; 6 (4) . https://dx.doi.org/10.2174/157488411798375949
DOI https://dx.doi.org/10.2174/157488411798375949 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Effects of Imidazolic Agonism on Blood Pressure, Sympathetic Activity, Left Ventricular Hypertrophy and Insulin Resistance
Current Hypertension Reviews Prevalence and Prognostic Value of Depression and Anxiety in Patients with Diabetic Foot Ulcers and Possibilities of their Treatment
Current Diabetes Reviews Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Antiaging Therapy: A Novel Target for Antilipolytic Drugs
Mini-Reviews in Medicinal Chemistry Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
Current Vascular Pharmacology The Impact of Cardiovascular Diseases on Cardiovascular Regulation During Exercise in Humans: Studies on Metaboreflex Activation Elicited by the Post-exercise Muscle Ischemia Method
Current Cardiology Reviews Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Current Pharmaceutical Analysis Harnessing Metabolomics for Nutrition Research
Current Pharmaceutical Biotechnology Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Role of Subclinical Iatrogenic Hyperthyroidism in the Setting of Heart Disease and Arrhythmic Burden
Endocrine, Metabolic & Immune Disorders - Drug Targets Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention
Current Pharmaceutical Biotechnology Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Pathophysiology of Necrotizing Enterocolitis: An Update
Current Pediatric Reviews Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design